Adma Biologics Inc

1. 1

   Election of Two Class I Directors

   ManagementBoard: FOR

   Elect two Class I directors (Alison C. Finger and Eduardo Rene Salas) to serve three-year terms expiring at the 2029 annual meeting.

2. 2

   Ratification of KPMG LLP as Independent Registered Public Accounting Firm for 2026

   ManagementBoard: FOR

   Ratify the Audit Committee’s appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.

   More detail

   This management proposal asks stockholders to ratify KPMG LLP as ADMA’s independent registered public accounting firm for fiscal year 2026. Management and the Audit Committee seek ratification as a sound corporate governance practice, even though the Audit Committee retains ultimate authority to appoint auditors. The proposal context includes a recent auditor change: CohnReznick resigned effective November 7, 2024, and KPMG was engaged beginning October 31, 2024 and performed the 2024 audit. The board recommends a FOR vote, citing its view that the appointment is advisable and in the company’s best interest; it also notes that ratification is advisory and non-binding, and that the Audit Committee will consider stockholder feedback if the vote is not approved. Shareholders should view this as routine but informative governance oversight of auditor selection and a signal about the Audit Committee’s confidence in KPMG following the 2024 transition.

3. 3

   Advisory Vote to Approve Named Executive Officer Compensation (Say-on-Pay

   ManagementBoard: FOR

   Non-binding, advisory vote to approve the compensation of the Company’s named executive officers as disclosed in the proxy statement.

   More detail

   The Say-on-Pay management proposal is a non-binding advisory vote asking shareholders to approve the compensation of ADMA’s named executive officers as disclosed. Management seeks shareholder support to validate its pay-for-performance approach, which ties executive pay to corporate and individual performance, with a mix of base salary, annual bonuses, and equity-based long-term incentives. The Compensation Committee argues that the program aligns executives’ interests with stockholders, uses benchmarking and a compensation consultant, and includes governance features such as clawback policy and stock ownership guidelines. The company points out strong 2025 performance metrics—record revenue, FDA approval of a yield enhancement process, product demand growth, and strategic transactions—which it says justify compensation outcomes. The board recommends a FOR vote while acknowledging the advisory nature of the vote and its commitment to consider stockholder feedback if substantial opposition occurs.

4. 4

   Transaction of Other Business Properly Brought Before the Meeting

   ManagementBoard: FOR

   Transaction of such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.

Upcoming shareholder meetings at Adma Biologics Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.

When is the Adma Biologics Inc 2026 annual meeting?

Adma Biologics Inc (ADMA) holds its 2026 annual shareholder meeting on Tuesday, June 2, 2026.

What is the record date for the Adma Biologics Inc 2026 meeting?

The record date for the Adma Biologics Inc 2026 meeting is Wednesday, April 8, 2026. Shareholders of record on or before that date are eligible to vote.

Who are the director nominees for Adma Biologics Inc's 2026 meeting?

The board is presenting 2 director nominees at the Adma Biologics Inc 2026 meeting, listed with their independence status and background.

What proposals will shareholders vote on at the Adma Biologics Inc 2026 meeting?

Shareholders will vote on 4 proposals at the Adma Biologics Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.